Madrigal Pharmaceuticals Stock Soars as Market Responds to Promising New NASH Medication
Friday, 15 March 2024, 12:19
Madrigal Pharmaceuticals stock surge with new NASH medication
Madrigal Pharmaceuticals (MDGL) experienced a notable surge in its stock price as Wall Street welcomed the company's latest NASH medication, Rezdiffra. This surge highlights the positive market sentiment towards the potential of the new drug in tackling NASH.
B. Riley upgrades
B. Riley analysts have upgraded their outlook on Madrigal Pharmaceuticals following the announcement of the new medication. This upgrade suggests that financial experts recognize the significance of Rezdiffra in the company's growth trajectory.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.